Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX 株式レポート

時価総額:US$5.2b

Crinetics Pharmaceuticals 将来の成長

Future 基準チェック /26

Crinetics Pharmaceuticals利益と収益がそれぞれ年間9%と67.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-40.3% 12.8%なると予測されています。

主要情報

9.0%

収益成長率

12.8%

EPS成長率

Biotechs 収益成長28.3%
収益成長率67.7%
将来の株主資本利益率-40.3%
アナリストカバレッジ

Good

最終更新日22 Nov 2024

今後の成長に関する最新情報

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

業績と収益の成長予測

NasdaqGS:CRNX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202650-435-451N/A9
12/31/202511-354-316-23712
12/31/20242-296-260-22012
9/30/20241-278-204-200N/A
6/30/20241-259-185-178N/A
3/31/20242-235-184-178N/A
12/31/20234-215-171-166N/A
9/30/20235-199-167-163N/A
6/30/20235-184-161-160N/A
3/31/20234-175-144-142N/A
12/31/20225-164-117-115N/A
9/30/20225-150-104-103N/A
6/30/20225-136-91-90N/A
3/31/20224-119-82-82N/A
12/31/20211-108-89-89N/A
9/30/2021N/A-98-82-82N/A
6/30/2021N/A-89-74-74N/A
3/31/2021N/A-79-70-70N/A
12/31/20200-74-62-62N/A
9/30/20200-67-60-60N/A
6/30/20201-63-55-55N/A
3/31/20201-59-52-52N/A
12/31/20191-50-47-46N/A
9/30/20192-44-40-39N/A
6/30/20192-38-32-31N/A
3/31/20192-31-24-23N/A
12/31/20182-27-21-19N/A
9/30/20182-21-17-16N/A
6/30/20182-16N/A-13N/A
3/31/20182-12N/A-11N/A
12/31/20172-9N/A-9N/A
12/31/20161-6N/A-5N/A

アナリストによる今後の成長予測

収入対貯蓄率: CRNX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRNX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CRNX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRNXの収益 ( 67.7% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: CRNXの収益 ( 67.7% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: CRNX 3 年以内に赤字になると予測されています。


成長企業の発掘